<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Muscle Relaxants: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i616.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i616.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i616.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i615.htm" title="Previous: Moxonidine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i617.htm" title="Next: Baclofen">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i616">Muscle Relaxants</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Muscle Relaxants</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i372.htm">Lithium</a></td><td>effects of  muscle relaxants enhanced by lithium </td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td>effects of  muscle relaxants enhanced by propranolol </td><td></td></tr></tbody></table><p><b>Baclofen</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

























<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td>enhanced hypotensive effect when  baclofen given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  baclofen given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td>increased sedative effect when  baclofen given with alcohol </td><td></td></tr><tr><td><a href="41001i26.htm">Alpha-blockers</a></td><td>enhanced hypotensive effect when  baclofen given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>enhanced hypotensive effect when  baclofen given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td>muscle relaxant effect of  baclofen enhanced by tricyclics </td><td></td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  baclofen given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>enhanced hypotensive effect when  baclofen given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  baclofen given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td>enhanced hypotensive effect when  baclofen given with clonidine </td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  baclofen given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  baclofen given with diuretics </td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td>increased sedative effect when  baclofen given with fentanyl </td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  baclofen given with hydralazine </td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td>excretion of  baclofen reduced by ibuprofen (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td>possible agitation, confusion and hallucinations when  baclofen given with levodopa </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td> baclofen possibly aggravates hyperkinesis caused by lithium </td><td></td></tr><tr><td><a href="41001i942.htm">Memantine</a></td><td>effects of  baclofen possibly modified by memantine </td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>enhanced hypotensive effect when  baclofen given with methyldopa </td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td>enhanced hypotensive effect when  baclofen given with minoxidil </td><td></td></tr><tr><td><a href="41001i98.htm">Morphine</a></td><td>increased sedative effect when  baclofen given with morphine </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  baclofen given with moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td>enhanced hypotensive effect when  baclofen given with nitrates </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td>excretion of  baclofen possibly reduced by NSAIDs (increased risk of toxicity)</td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  baclofen given with sodium nitroprusside </td><td></td></tr></tbody></table><p><b>Dantrolene</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i468.htm">Diltiazem</a></td><td>possible increased risk of ventricular arrhythmias when <i>intravenous</i>  dantrolene given with diltiazem—manufacturer of diltiazem advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i942.htm">Memantine</a></td><td>effects of  dantrolene possibly modified by memantine </td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>avoidance of <i>intravenous</i>  dantrolene advised by manufacturer of verapamil </td><td></td></tr></tbody></table><p><b>Methocarbamol</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i20.htm">Alcohol</a></td><td>increased sedative effect when  methocarbamol given with alcohol </td><td></td></tr></tbody></table><p><b>Tizanidine</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>























<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td>enhanced hypotensive effect when  tizanidine given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  tizanidine given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td>increased sedative effect when  tizanidine given with alcohol </td><td></td></tr><tr><td><a href="41001i26.htm">Alpha-blockers</a></td><td>enhanced hypotensive effect when  tizanidine given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>enhanced hypotensive effect when  tizanidine given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  tizanidine given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>possible enhanced hypotensive effect and bradycardia when  tizanidine given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  tizanidine given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td>possible increased risk of bradycardia when  tizanidine given with cardiac glycosides </td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td class="cBV"><b>plasma concentration of  tizanidine increased by ciprofloxacin (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td>enhanced hypotensive effect when  tizanidine given with clonidine </td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  tizanidine given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  tizanidine given with diuretics </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>plasma concentration of  tizanidine increased by fluvoxamine (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  tizanidine given with hydralazine </td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>enhanced hypotensive effect when  tizanidine given with methyldopa </td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td>enhanced hypotensive effect when  tizanidine given with minoxidil </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  tizanidine given with moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td>enhanced hypotensive effect when  tizanidine given with nitrates </td><td></td></tr><tr><td><a href="41001i197.htm">Norfloxacin</a></td><td>plasma concentration of  tizanidine possibly increased by norfloxacin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  tizanidine possibly increased by oestrogens (increased risk of toxicity)</td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>plasma concentration of  tizanidine possibly increased by progestogens (increased risk of toxicity)</td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  tizanidine given with sodium nitroprusside </td><td></td></tr></tbody></table><p><b>Muscle Relaxants, non-depolarising</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td class="cBV"><b>effects of  non-depolarising muscle relaxants enhanced by aminoglycosides </b></td><td></td></tr><tr><td><a href="41001i46.htm">Anaesthetics, General (volatile liquids)</a></td><td>effects of  non-depolarising muscle relaxants enhanced by volatile liquid general anaesthetics </td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>effects of  non-depolarising muscle relaxants possibly enhanced by calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>muscle relaxant effect of  non-depolarising muscle relaxants antagonised by carbamazepine (accelerated recovery from neuromuscular blockade)</td><td></td></tr><tr><td><a href="41001i159.htm">Clindamycin</a></td><td class="cBV"><b>effects of  non-depolarising muscle relaxants enhanced by clindamycin </b></td><td></td></tr><tr><td><a href="41001i657.htm">Donepezil</a></td><td>effects of  non-depolarising muscle relaxants possibly antagonised by donepezil </td><td></td></tr><tr><td><a href="41001i650.htm">Edrophonium</a></td><td>effects of  non-depolarising muscle relaxants antagonised by edrophonium </td><td></td></tr><tr><td><a href="41001i608.htm">Magnesium (parenteral)</a></td><td>effects of  non-depolarising muscle relaxants enhanced by parenteral magnesium </td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td>effects of  non-depolarising muscle relaxants antagonised by neostigmine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>muscle relaxant effect of  non-depolarising muscle relaxants antagonised by phenytoin (accelerated recovery from neuromuscular blockade)</td><td></td></tr><tr><td><a href="41001i179.htm">Piperacillin</a></td><td>effects of  non-depolarising muscle relaxants enhanced by piperacillin </td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td class="cBV"><b>effects of  non-depolarising muscle relaxants enhanced by polymyxins </b></td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td>effects of  non-depolarising muscle relaxants antagonised by pyridostigmine </td><td></td></tr><tr><td><a href="41001i849.htm">Rivastigmine</a></td><td>effects of  non-depolarising muscle relaxants antagonised by rivastigmine </td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>effects of  non-depolarising muscle relaxants enhanced by verapamil </td><td></td></tr></tbody></table><p><b>Atracurium</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i45.htm">Ketamine</a></td><td>effects of  atracurium enhanced by ketamine </td><td></td></tr></tbody></table><p><b>Cisatracurium</b> belongs to
      <b>Muscle Relaxants</b>
          but has no specific interaction information.
        </p><p><b>Mivacurium</b> belongs to
      <b>Muscle Relaxants</b>
          but has no specific interaction information.
        </p><p><b>Pancuronium</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>effects of  pancuronium possibly antagonised by corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr></tbody></table><p><b>Rocuronium</b> belongs to
      <b>Muscle Relaxants</b>
          but has no specific interaction information.
        </p><p><b>Vecuronium</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>effects of  vecuronium possibly antagonised by corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr></tbody></table><p><b>Muscle Relaxants, depolarising</b> belongs to
      <b>Muscle Relaxants</b>
          but has no specific interaction information.
        </p><p><b>Suxamethonium</b> belongs to
      <b>Muscle Relaxants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>
























<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td class="cBV"><b>effects of  suxamethonium enhanced by aminoglycosides </b></td><td></td></tr><tr><td><a href="41001i46.htm">Anaesthetics, General (volatile liquids)</a></td><td>effects of  suxamethonium enhanced by volatile liquid general anaesthetics </td><td></td></tr><tr><td><a href="41001i721.htm">Bambuterol</a></td><td>effects of  suxamethonium enhanced by bambuterol </td><td></td></tr><tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td>risk of ventricular arrhythmias when  suxamethonium given with cardiac glycosides </td><td></td></tr><tr><td><a href="41001i159.htm">Clindamycin</a></td><td class="cBV"><b>effects of  suxamethonium enhanced by clindamycin </b></td><td></td></tr><tr><td><a href="41001i502.htm">Cyclophosphamide</a></td><td>effects of  suxamethonium enhanced by cyclophosphamide </td><td></td></tr><tr><td><a href="41001i657.htm">Donepezil</a></td><td>effects of  suxamethonium possibly enhanced by donepezil </td><td></td></tr><tr><td><a href="41001i650.htm">Edrophonium</a></td><td>effects of  suxamethonium enhanced by edrophonium </td><td></td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td>effects of  suxamethonium enhanced by galantamine </td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td>neuromuscular blockade enhanced and prolonged when  suxamethonium given with lidocaine </td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i608.htm">Magnesium (parenteral)</a></td><td>effects of  suxamethonium enhanced by parenteral magnesium </td><td></td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>effects of  suxamethonium enhanced by metoclopramide </td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td>effects of  suxamethonium enhanced by neostigmine </td><td></td></tr><tr><td><a href="41001i259.htm">Phenelzine</a></td><td>effects of  suxamethonium enhanced by phenelzine </td><td></td></tr><tr><td><a href="41001i179.htm">Piperacillin</a></td><td>effects of  suxamethonium enhanced by piperacillin </td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td class="cBV"><b>effects of  suxamethonium enhanced by polymyxins </b></td><td></td></tr><tr><td><a href="41001i376.htm">Promazine</a></td><td>effects of  suxamethonium possibly enhanced by promazine </td><td></td></tr><tr><td><a href="41001i44.htm">Propofol</a></td><td class="cBV"><b>increased risk of myocardial depression and bradycardia when  suxamethonium given with propofol </b></td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td>effects of  suxamethonium enhanced by pyridostigmine </td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td>effects of  suxamethonium possibly enhanced by quinine </td><td></td></tr><tr><td><a href="41001i849.htm">Rivastigmine</a></td><td>effects of  suxamethonium enhanced by rivastigmine </td><td></td></tr><tr><td><a href="41001i504.htm">Thiotepa</a></td><td>effects of  suxamethonium enhanced by thiotepa </td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td class="cBV"><b>effects of  suxamethonium enhanced by vancomycin </b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>effects of  suxamethonium enhanced by verapamil </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i617.htm" title="Baclofen">Baclofen</a></li><li><a href="41001i618.htm" title="Dantrolene">Dantrolene</a></li><li><a href="41001i619.htm" title="Methocarbamol">Methocarbamol</a></li><li><a href="41001i805.htm" title="Tizanidine">Tizanidine</a></li><li id="_41001i620"><a href="41001i620.htm" title="Muscle Relaxants, non-depolarising">Muscle Relaxants, non-depolarising</a></li><li id="_41001i627"><a href="41001i627.htm" title="Muscle Relaxants, depolarising">Muscle Relaxants, depolarising</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i615.htm">Previous: Moxonidine</a> | <a class="top" href="41001i616.htm#">Top</a> | <a accesskey="]" href="41001i617.htm">Next: Baclofen</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>